FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205651323> ?p ?o ?g. }

• W4205651323 endingPage "121" @default.
• W4205651323 startingPage "121" @default.
• W4205651323 abstract "<h3>Importance</h3> Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in which efficacy was expected. <h3>Objective</h3> To evaluate the long-term safety and effectiveness of intravenous edaravone therapy for patients with ALS in a real-world clinical setting. <h3>Design, Setting, and Participants</h3> Multicenter, propensity score–matched cohort study conducted between June 2017 and March 2020 at 12 academic ALS referral centers associated with the German Motor Neuron Disease Network. Of 1440 patients screened, 738 were included in propensity score matching. Final analyses included 324 patients with ALS comprising 194 patients who started intravenous edaravone treatment (141 received ≥4 consecutive treatment cycles; 130 matched) and 130 propensity score–matched patients with ALS receiving standard therapy. All patients had probable or definite ALS according to the El Escorial criteria, with disease onset between December 2012 and April 2019. Subgroups were defined by applying the MCI186-ALS19 study inclusion criteria to evaluate whether patients would have been considered eligible (EFAS) or ineligible (non-EFAS). <h3>Exposures</h3> Intravenous edaravone plus riluzole vs riluzole only. <h3>Main Outcomes and Measures</h3> Patient characteristics and systematic safety assessment for patients who received at least 1 dose of intravenous edaravone. Effectiveness assessment of edaravone was conducted among patients who received at least 4 treatment cycles compared with propensity score–matched patients with ALS who received only standard therapy. Primary outcome was disease progression measured by decrease in the ALS Functional Rating Scale–Revised (ALSFRS-R) score. Secondary outcomes were survival probability, time to ventilation, and change in disease progression before vs during treatment. To account for the matched design, patients receiving edaravone and their corresponding matched controls were regarded as related samples in disease progression analyses; stratification for propensity score quintiles was used for survival probability and time to ventilation analyses. <h3>Results</h3> A total of 194 patients started intravenous edaravone treatment; 125 (64%) were male, and the median age was 57.5 years (IQR, 50.7-63.8 years). Potential adverse effects were observed in 30 cases (16%), most notably infections at infusion sites and allergic reactions. Disease progression among 116 patients treated for a median of 13.9 months (IQR, 8.9-19.9 months) with edaravone did not differ from 116 patients treated for a median of 11.2 months (IQR, 6.4-20.0 months) with standard therapy (ALSFRS-R points/month, −0.91 [95% CI, −0.69 to −1.07] vs −0.85 [95% CI, −0.66 to −0.99];<i>P</i> = .37). No significant differences were observed in the secondary end points of survival probability, time to ventilation, and change in disease progression. Similarly, outcomes between patients treated with edaravone and matched patients did not differ within the EFAS and non-EFAS subgroups. <h3>Conclusions and Relevance</h3> This cohort study using propensity score matching found that, although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit. Intravenous edaravone may not provide a clinically relevant additional benefit compared with standard therapy alone." @default.
• W4205651323 created "2022-01-26" @default.
• W4205651323 creator A5000794291 @default.
• W4205651323 creator A5002895582 @default.
• W4205651323 creator A5005633849 @default.
• W4205651323 creator A5008484351 @default.
• W4205651323 creator A5011294521 @default.
• W4205651323 creator A5015487716 @default.
• W4205651323 creator A5021302300 @default.
• W4205651323 creator A5031675925 @default.
• W4205651323 creator A5044789123 @default.
• W4205651323 creator A5046815322 @default.
• W4205651323 creator A5053690690 @default.
• W4205651323 creator A5057195222 @default.
• W4205651323 creator A5059133881 @default.
• W4205651323 creator A5062971675 @default.
• W4205651323 creator A5063407589 @default.
• W4205651323 creator A5064692134 @default.
• W4205651323 creator A5067799843 @default.
• W4205651323 creator A5070561307 @default.
• W4205651323 creator A5071062652 @default.
• W4205651323 creator A5079119009 @default.
• W4205651323 creator A5079587912 @default.
• W4205651323 creator A5082795436 @default.
• W4205651323 creator A5083277369 @default.
• W4205651323 creator A5084011375 @default.
• W4205651323 creator A9999999999 @default.
• W4205651323 date "2022-02-01" @default.
• W4205651323 modified "2023-10-11" @default.
• W4205651323 title "Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis" @default.
• W4205651323 cites W1989011562 @default.
• W4205651323 cites W2022925950 @default.
• W4205651323 cites W2034454495 @default.
• W4205651323 cites W2054693618 @default.
• W4205651323 cites W2128167427 @default.
• W4205651323 cites W2141155633 @default.
• W4205651323 cites W2161938104 @default.
• W4205651323 cites W2163438871 @default.
• W4205651323 cites W2314689571 @default.
• W4205651323 cites W2526461845 @default.
• W4205651323 cites W2616124858 @default.
• W4205651323 cites W2750922690 @default.
• W4205651323 cites W2753425250 @default.
• W4205651323 cites W2761063990 @default.
• W4205651323 cites W2799651844 @default.
• W4205651323 cites W2899021909 @default.
• W4205651323 cites W2916769868 @default.
• W4205651323 cites W2917925658 @default.
• W4205651323 cites W2953834891 @default.
• W4205651323 cites W2981269454 @default.
• W4205651323 cites W3024365540 @default.
• W4205651323 cites W3036311590 @default.
• W4205651323 cites W3062645889 @default.
• W4205651323 cites W3089885940 @default.
• W4205651323 cites W3098171944 @default.
• W4205651323 cites W3137121183 @default.
• W4205651323 cites W4239728164 @default.
• W4205651323 cites W4240840833 @default.
• W4205651323 cites W4248518818 @default.
• W4205651323 cites W4251371241 @default.
• W4205651323 cites W4252979096 @default.
• W4205651323 cites W4292528167 @default.
• W4205651323 doi "https://doi.org/10.1001/jamaneurol.2021.4893" @default.
• W4205651323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35006266" @default.
• W4205651323 hasPublicationYear "2022" @default.
• W4205651323 type Work @default.
• W4205651323 citedByCount "57" @default.
• W4205651323 countsByYear W42056513232022 @default.
• W4205651323 countsByYear W42056513232023 @default.
• W4205651323 crossrefType "journal-article" @default.
• W4205651323 hasAuthorship W4205651323A5000794291 @default.
• W4205651323 hasAuthorship W4205651323A5002895582 @default.
• W4205651323 hasAuthorship W4205651323A5005633849 @default.
• W4205651323 hasAuthorship W4205651323A5008484351 @default.
• W4205651323 hasAuthorship W4205651323A5011294521 @default.
• W4205651323 hasAuthorship W4205651323A5015487716 @default.
• W4205651323 hasAuthorship W4205651323A5021302300 @default.
• W4205651323 hasAuthorship W4205651323A5031675925 @default.
• W4205651323 hasAuthorship W4205651323A5044789123 @default.
• W4205651323 hasAuthorship W4205651323A5046815322 @default.
• W4205651323 hasAuthorship W4205651323A5053690690 @default.
• W4205651323 hasAuthorship W4205651323A5057195222 @default.
• W4205651323 hasAuthorship W4205651323A5059133881 @default.
• W4205651323 hasAuthorship W4205651323A5062971675 @default.
• W4205651323 hasAuthorship W4205651323A5063407589 @default.
• W4205651323 hasAuthorship W4205651323A5064692134 @default.
• W4205651323 hasAuthorship W4205651323A5067799843 @default.
• W4205651323 hasAuthorship W4205651323A5070561307 @default.
• W4205651323 hasAuthorship W4205651323A5071062652 @default.
• W4205651323 hasAuthorship W4205651323A5079119009 @default.
• W4205651323 hasAuthorship W4205651323A5079587912 @default.
• W4205651323 hasAuthorship W4205651323A5082795436 @default.
• W4205651323 hasAuthorship W4205651323A5083277369 @default.
• W4205651323 hasAuthorship W4205651323A5084011375 @default.
• W4205651323 hasAuthorship W4205651323A9999999999 @default.
• W4205651323 hasBestOaLocation W42056513232 @default.
• W4205651323 hasConcept C126322002 @default.
• W4205651323 hasConcept C167135981 @default.

• next